Compounds > thiazoles
Page last updated: 2024-08-21

thiazoles and vx680

thiazoles has been researched along with vx680 in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (63.64)29.6817
2010's4 (36.36)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Biggs, WH; Chao, LH; Kuriyan, J; Lockhart, DJ; Milanov, ZV; Patel, HK; Sawyers, CL; Seeliger, M; Shah, NP; Treiber, DK; Young, MA; Zarrinkar, PP1
Tuma, RS1
Kimura, S1
Branford, S; Hughes, TP; Nicoll, JM; Paquette, RL; Sawyers, CL; Shah, NP; Skaggs, BJ1
Thomas, X1
Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A1
Del Cañizo, MC; González, M; Gonzalez, T; Lopez-Jimenez, J; Sanchez-Guijo, FM; Santamaría, C1
Fei, F; Groffen, J; Heisterkamp, N; Stoddart, S1
Dino, PM; Forman, SJ; Jove, R; Kirschbaum, MH; Kowolik, CM; Kretzner, L; Scuto, A; Ventura, P; Wu, J; Yen, Y1
Chowdhury, A; Chowdhury, S; Tsai, MY1
Liu, S; Ouchi, T; Saeki, T; Shionome, Y; Yan, L1

Reviews

3 review(s) available for thiazoles and vx680

ArticleYear
[Novel anti-CML agents beyond imatinib].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2007, Volume: 48, Issue:6

    Topics: Adenosine Triphosphate; Aniline Compounds; Antineoplastic Agents; Benzamides; Benzene Derivatives; Binding Sites; Binding, Competitive; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles

2007
[Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
    Bulletin du cancer, 2007, Volume: 94, Issue:10

    Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Benzenesulfonates; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles

2007
[Novel medical treatment modalities in hematology].
    Ugeskrift for laeger, 2008, Jun-09, Volume: 170, Issue:24

    Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine

2008

Other Studies

8 other study(ies) available for thiazoles and vx680

ArticleYear
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.
    Cancer research, 2006, Jan-15, Volume: 66, Issue:2

    Topics: Aurora Kinases; Benzamides; Catalytic Domain; Crystallography; Dasatinib; Drug Resistance, Neoplasm; Escherichia coli; Fusion Proteins, bcr-abl; Genes, abl; Humans; Hydrogen Bonding; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Thiazoles

2006
With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model.
    Journal of the National Cancer Institute, 2007, Feb-07, Volume: 99, Issue:3

    Topics: Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Benzamides; Dasatinib; Drug Administration Schedule; Drug Costs; Fusion Proteins, bcr-abl; HIV Infections; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Threonine; United States

2007
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
    The Journal of clinical investigation, 2007, Volume: 117, Issue:9

    Topics: Alleles; Amino Acid Motifs; Animals; Benzamides; Cell Line; Dasatinib; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Sensitivity and Specificity; Thiazoles; Valine

2007
Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia.
    Leukemia research, 2009, Volume: 33, Issue:6

    Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; Dasatinib; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; Thiazoles

2009
Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Aurora Kinases; Cells, Cultured; Dasatinib; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Embryo, Mammalian; Fusion Proteins, bcr-abl; Humans; Mice; Mice, Knockout; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Thiazoles; Treatment Outcome

2010
Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
    Cancer research, 2011, Jun-01, Volume: 71, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Aurora Kinases; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Cyclohexanecarboxylic Acids; Drug Synergism; Gene Expression Regulation, Neoplastic; Genes, myc; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoblotting; Lymphoma; MicroRNAs; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-myc; Telomerase; Thiazoles; Vorinostat

2011
A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Aurora Kinase A; Aurora Kinases; Biomarkers; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cyclin B; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Histones; Humans; Lymphoma, Non-Hodgkin; Microtubule-Associated Proteins; Neoplasm Proteins; Nuclear Proteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; RNA Interference; RNA, Small Interfering; Thiazoles; Transcription Factors; Xenopus laevis; Xenopus Proteins

2012
Integrity of p53 associated pathways determines induction of apoptosis of tumor cells resistant to Aurora-A kinase inhibitors.
    PloS one, 2013, Volume: 8, Issue:1

    Topics: Animals; Apoptosis; Aurora Kinase A; Aurora Kinases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Female; HCT116 Cells; Humans; Mice; Neoplasms; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Thiazoles; TOR Serine-Threonine Kinases; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2013